Severe acute respiratory syndrome (SARS) coronavirus (CoV) contains a spike (S) protein that binds to a receptor molecule (angiotensin-converting enzyme 2; ACE2), induces membrane fusion, and serves as a neutralizing epitope. To study the functions of the S protein, we describe here the generation of SARS-CoV S protein-bearing vesicular stomatitis virus (VSV) pseudotype using a VSV⌬G*/GFP system in which the G gene is replaced by the green fluorescent protein (GFP) gene (VSV-SARS-CoV-St19/GFP). Partial deletion of the cytoplasmic domain of SARS-CoV S protein (SARS-CoV-St19) allowed efficient incorporation into the VSV particle that enabled the generation of a high titer of pseudotype virus. Neutralization assay with anti-SARS-CoV antibody revealed that VSV-SARS-St19/GFP pseudotype infection is mediated by SARS-CoV S protein. The VSV⌬G*/SEAP system, which secretes alkaline phosphatase instead of GFP, was also generated as a VSV pseudotype having SARS-CoV S protein (VSV-SARS-CoV-St19/SEAP). This system enabled high-throughput analysis of SARS-CoV S protein-mediated cell entry by measuring alkaline phosphatase activity. Thus, VSV pseudotyped with SARS-CoV S protein is useful for developing a rapid detection system for neutralizing antibody specific for SARS-CoV infection as well as studying the S-mediated cell entry of SARS-CoV.
Introduction
Entry of SARS coronavirus (SARS-CoV) into target cells is mediated by binding of the viral spike (S) protein to the receptor molecules, angiotensinconverting-enzyme 2 (ACE2) (1). Studies on SARS using infectious SARS-CoV require care because of the highly pathogenic nature of this virus, so an alternative methodology is needed. Recently, pseudotyped retrovirus particles bearing SARS-CoV S protein have been generated by several laboratories (2-4) . These pseudotyped viruses have been shown to have a cell tropism identical to authentic SARS-CoV and their infectivity is dependent on ACE2, indicating that the infection is mediated solely by SARS-CoV S protein. Pseudotyped viruses have proved to be a safe viral entry model because of an inability to produce infectious progeny virus. A quantitative assay of pseudovirus infection could facilitate the research on SARS-CoV entry, cell tropism, and neutralization antibody.
Another pseudotyping system with a vesicular stomatitis virus (VSV) particle was previously reported to produce pseudotypes of envelope glycoprotein of several RNA viruses (i.e., measles virus, hantavirus, Ebola virus, and hepatitis C virus) (5-8). This system (VSV⌬G*/GFP system) may be useful for research on envelope glycoprotein owing to its ability to grow high titers in a variety of cell lines. The pseudotype virus titer obtained from the VSV⌬G*/GFP system (>10 5 infectious units (IU)/ml) is generally higher than that of the pseudotyped retrovirus system (6). Furthermore, infection of pseudotyped VSV in target cells can be detected as GFP-positive cells within 16 h postinfection (hpi) because of the powerful GFP-expression in the VSV⌬G*/GFP system (6). In contrast, the time required for the pseudotyped retrovirus system to detect infection is 48 hpi (9,10), which is similar to that for the SARS-CoV to replicate to the level of producing plaques or cytopathic effects on infected cells. Thus, pseudotyping of SARS-CoV S protein using the VSV⌬G*/GFP system may have greater advantages than retrovirus pseudotypes for studying the function of SARS-CoV S protein as well as for developing a rapid system for detection of neutralizing antibody specific for SARS-CoV.
Here we describe protocols for introducing SARS-CoV-S protein into VSV particles using the VSV⌬G*/GFP system. The infection of VSV pseudotype bearing SARS-CoV S protein (VSV-SARS-St19/GFP) was easily detected in target cells as an expression of the GFP protein. The following methods were originally designed to produce VSV-SARS-St19/GFP and to measure the infection efficiency. In addition to a significant advantage of the VSV-SARS-St19/GFP for safe and rapid analyses of infection, the VSV⌬G*/SEAP system, in which the G gene is replaced with the secreted alkaline phosphatase (SEAP) gene, may be superior to high-throughput quantitative analysis of S-mediated cell entry. The protocol for analyzing pseudotypes using the VSV⌬G*/SEAP system is also described briefly. 1 ). 6. The VSV⌬G*/GFP-G or VSV⌬G*/SEAP-G (see Note 2). 7. 0.22-m pore size sterile filter. 8. Digital fluorescence microscope for detecting GFP expression. 9. Reporter Assay Kit-SEAP (Toyobo, Osaka, Japan) and luminescence microplate reader for SEAP activity analyses.
Materials

Methods
A schematic description of the production of VSV pseudotype is shown in Fig. 1. 
Expression of SARS-CoV S Protein and Production of VSV Pseudotype
Determining Infectivity of VSV-SARS-St19/GFP
The infectivity of VSV-SARS-St19/GFP, harboring the VSV⌬G*/GFP genome, can be determined as the number of GFP-positive cells. 1 . Mix serially diluted VSV-SARS-St19/GFP with DMEM-5%FCS and inoculate the mixture into Vero E6 cells seeded in 96-well culture plates. 
Incubate the cells in a CO 2 incubator for 7 h. Longer incubation (overnight to 24 h)
may be beneficial for clearer fluorescent intensities on GFP-positive cells. 3. Detect GFP-positive cells using fluorescent microscopy (Fig. 2) . 4 . Determine the IU of the pseudotype. The IU is defined as a virus titer endpoint determined by limiting dilution. The technique uses 96-well plates. Twenty l of supernatants from cell cultures are added to the wells with an equal volume of endogenous alkaline phosphatase inhibitor. Incubate the mixture at 37 • C for 30 min. Next, add 160 l of chemiluminescent substrate to the mixture. An incubation of 30 min at 37 • C allows the chemiluminescence reaction. Use a luminescence microplate reader to detect the chemiluminescence signal.
Neutralization Assay of VSV-SARS-St19/GFP Infection Using Antibodies Specific to SARS-CoV
Notes
1. To generate high virus titer of VSV pseudotype, prepare the plasmid encoding a C-terminal truncated version of the S protein, because it has been shown that truncation of C-terminal 19 amino acids leads to efficient incorporation of S protein into the VSV particles, and then the VSV pseudotype shows an efficient infection to target cells (11). 2. The VSV⌬G*/GFP-G is a VSV-G protein-bearing VSV pseudotype in which VSV-G gene is replaced with GFP gene. The VSV⌬G*/SEAP-G is same as VSV⌬G*/GFP-G except for having SEAP gene instead of the GFP gene.
Pseudotypes having VSV-G protein are used as "seed" viruses for generating S protein bearing VSV pseudotypes. Since the VSV⌬G*/GFP or VSV⌬G*/SEAP system was developed by Prof. M. A. Whitt (University of Tennessee Health Science Center, TN), ask him for sharing and using the system when starting experiments. 3. As the SEAP gene is obtained by modification of human placental alkaline phosphatase gene, some cell lines derived from placenta that express alkaline phosphatase similar to SEAP should not be used as target cells. For the analysis of VSV-SARS-St19/SEAP infection, we suggest using Vero E6 cells that show a very low level of alkaline phosphatase activity in the culture supernatant. 4. The medium containing VSV-SARS-St19/SEAP may have strong SEAP activity since it is derived from culture medium of 293T cells inoculated VSV⌬G*/ SEAP-G (see steps 3-6 in Section 3.1). In order to remove carryover SEAP activities derived from VSV⌬G*/SEAP-G the Vero E6 cells have to be washed with PBS at least three times.
